Sisram's Thailand Gambit: A Blueprint for Southeast Asia's Beauty Market

HONG KONG – June 22, 2026

Global wellness group Sisram Medical has initiated a significant strategic push into Southeast Asia, designating Thailand as its core regional hub. The Hong Kong-listed firm (1696.HK) announced the official rollout of its Soprano Titanium energy-based device (EBD) across the country, a move that complements the sustained growth of its flagship injectable, Profhilo. This dual-pronged offensive is not merely an expansion but a calculated maneuver to establish a dominant foothold in one of the world's most dynamic medical aesthetics markets, creating a blueprint for growth across the wider Asia-Pacific (APAC) region.

The company's strategy validates its "dual-engine" growth model, which pairs advanced EBD technology with a rapidly expanding injectables portfolio. By establishing a direct sales operation in Thailand in 2025 and leveraging long-standing partnerships with leading clinics, Sisram has laid the groundwork for what it hopes will be a period of substantial regional growth, capitalizing on local demand and a thriving medical tourism sector.

A Dual-Engine Strategy in a Vibrant Market

Sisram's investment in Thailand is timed to perfection. The country's medical aesthetics market is not just growing; it's exploding. Projections estimate the market could reach USD 3.45 billion by 2030, expanding at a compound annual growth rate (CAGR) of 9.7%. This rapid expansion is fueled by a confluence of powerful trends: rising disposable incomes, a cultural emphasis on personal appearance, and a significant demographic shift.

Thailand's aging population, with nearly one-fifth of its citizens over 60, is driving strong demand for anti-aging solutions. Simultaneously, younger generations, including Gen Z, are embracing aesthetic procedures more than ever, seeking non-invasive treatments that offer impressive results with minimal downtime. This has created a surge in demand for products like facial fillers, laser skin resurfacing, and advanced bio-remodeling injectables—the very categories where Sisram is concentrating its efforts. The company's Soprano Titanium, an advanced laser hair removal and skin tightening platform, and Profhilo, a unique hyaluronic acid-based injectable, are positioned directly at the heart of this demand.

"Thailand stands out as one of Southeast Asia's most vibrant medical aesthetics markets, underpinned by sound healthcare infrastructure, strong domestic demand and a booming medical tourism sector," commented Mr. Eyal Ben David, CEO of Sisram Medical. "Over the past year, we have ramped up local investment and expanded our presence, achieving healthy growth in both revenue and profit."

Redefining Treatments with an Integrated Approach

What sets Sisram's strategy apart is its focus on integration. The company is moving beyond selling individual products and is pioneering comprehensive treatment protocols that combine its EBD and injectable technologies. This synergistic approach creates value that standalone products cannot match.

For instance, clinics can now offer patients a customized regimen that pairs the skin tightening and contouring capabilities of the Soprano Titanium with the deep hydration and bio-remodeling benefits of Profhilo. The former uses laser energy to target deeper tissue structures, while the latter works to improve skin quality, elasticity, and firmness from within by stimulating collagen and elastin production. This combination allows practitioners to address multiple aspects of facial aging in a single, cohesive treatment plan, leading to enhanced clinical outcomes and higher patient satisfaction.

This integrated model is a powerful competitive differentiator. For partner clinics, it translates into an ability to offer more sophisticated, high-value treatment packages, maximizing the utility of Sisram's product ecosystem. This not only boosts revenue and profitability but also strengthens customer retention by delivering superior results. For Sisram, it drives deeper product penetration and solidifies its role as a strategic partner rather than a simple vendor.

Capitalizing on Thailand's Medical Tourism Boom

Sisram’s expansion is also strategically positioned to capture a significant share of Thailand’s lucrative medical tourism market. The nation is a global magnet for individuals seeking high-quality, affordable medical care, with aesthetic procedures being a primary draw. An estimated 60% of all medical tourists visiting Thailand do so for cosmetic enhancements, and the sector is projected to reach over USD 3.4 billion by 2034.

These international patients, often from the US, Europe, and Australia, are sophisticated consumers seeking the latest technology and proven results at a fraction of the cost back home. The introduction of globally recognized, premium brands like Soprano Titanium and Profhilo directly addresses this demand. By equipping Thai clinics with state-of-the-art technology, Sisram helps them attract and retain this discerning international clientele, further cementing Thailand's reputation as a world-class medical hub.

"Our progress in Thailand validates the strength of our global product portfolio, localized operating model and dual-growth strategy," Ben David continued. This validation is critical as the company looks to replicate its success in other fast-growing APAC markets.

A Strategic Hub for Broader APAC Ambitions

The moves in Thailand are a microcosm of Sisram’s broader global strategy. The company has methodically shifted towards a direct sales model and a "glocalization" approach, combining its global product portfolio with deep local operational expertise. The results are evident in its financial performance. In 2025, the APAC region became the company's largest revenue contributor, surging 26.9% year-over-year to US$147.4 million and accounting for over 40% of total revenue. Thailand, alongside China and South Korea, was a key driver of this impressive growth.

With the Thai operations now established as a strategic base, Sisram plans to deepen its investment in the region. The company has a pipeline of additional EBD models currently navigating the local regulatory process, with launches anticipated in the second half of 2026. This will further diversify its portfolio and strengthen its integrated treatment offerings.

Looking ahead, the firm intends to leverage its Thai hub to expand its customer footprint, enhance medical education and technical support, and deepen the synergies between its business lines across Southeast Asia. Backed by its majority shareholder, Fosun Pharma, Sisram is well-positioned to continue its transformation from a device manufacturer into an all-encompassing wellness platform.

"Going forward, we will further entrench Thailand as our key strategic base for the APAC region," stated Ben David. "Through ongoing innovation and premium solution offerings, we are well positioned to serve local consumers and the fast-growing medical tourism market, and deliver sustainable, high-quality growth across the broader APAC market."